ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000801

Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation

Identifieur interne : 000801 ( PascalFrancis/Corpus ); précédent : 000800; suivant : 000802

Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation

Auteurs : Rodrigo Mercado ; Constantine Constantoyannis ; Tomasz Mandat ; Ajit Kumar ; Michael Schulzer ; A. Jon Stoessl ; Christopher R. Honey

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0518102

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Attente, Effet placebo, Homme, Noyau sousthalamique, Placebo, Stimulation cérébrale profonde.

English descriptors

KwdEn :
- Deep brain stimulation, Expectation, Human, Nervous system diseases, Parkinson disease, Placebo, Placebo effect, Subthalamic nucleus.

Abstract

To determine whether the degree to which a patient with Parkinson's disease expects therapeutic benefit from subthalamic nucleus-deep brain stimulation (STN-DBS) influences the magnitude of his or her improved motor response, 10 patients with idiopathic Parkinson's and bilateral STN-DBS were tested after a 12-hour period off medication and stimulation. Four consecutive UPDRS III scores were performed in the following conditions: (a) stimulation OFF, patient aware; (b) stimulation OFF, patient blind; (c) stimulation ON, patient aware; and (d) stimulation ON, patient blind. Statistical significance (P = 0.0001) was observed when comparing main effect ON versus OFF (mean ON: 32.55; mean OFF: 49.15). When the stimulation was OFF, patients aware of this condition had higher UPDRS motor scores than when they were blinded (mean: 50.7 vs. 47.6). With the stimulation ON, UPDRS motor scores were lower when the patients were aware of the stimulation compared with when they were blinded (mean: 30.6 vs. 34.5). The interaction between these levels was significant (P = 0.049). This variation was important for bradykinesia and was not significant for tremor and rigidity. The authors conclude that the information about the condition of the stimulation enhanced the final clinical effect in opposite directions. The results presented support the role of expectation and placebo effects in STN-DBS in Parkinson's disease patients.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation`
A11	`01`	`1`		`@1 MERCADO (Rodrigo)`
A11	`02`	`1`		`@1 CONSTANTOYANNIS (Constantine)`
A11	`03`	`1`		`@1 MANDAT (Tomasz)`
A11	`04`	`1`		`@1 KUMAR (Ajit)`
A11	`05`	`1`		`@1 SCHULZER (Michael)`
A11	`06`	`1`		`@1 STOESSL (A. Jon)`
A11	`07`	`1`		`@1 HONEY (Christopher R.)`
A14	`01`			`@1 Surgical Centre for Movement Disorders, University of British Columbia @2 British Columbia @3 CAN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 7 aut.`
A14	`02`			`@1 Pacific Parkinson's Disease Research Center, University of British Columbia @2 British Columbia @3 CAN @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A20				`@1 1457-1461`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000158780860240`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 32 ref.`
A47	`01`	`1`		`@0 06-0518102`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 To determine whether the degree to which a patient with Parkinson's disease expects therapeutic benefit from subthalamic nucleus-deep brain stimulation (STN-DBS) influences the magnitude of his or her improved motor response, 10 patients with idiopathic Parkinson's and bilateral STN-DBS were tested after a 12-hour period off medication and stimulation. Four consecutive UPDRS III scores were performed in the following conditions: (a) stimulation OFF, patient aware; (b) stimulation OFF, patient blind; (c) stimulation ON, patient aware; and (d) stimulation ON, patient blind. Statistical significance (P = 0.0001) was observed when comparing main effect ON versus OFF (mean ON: 32.55; mean OFF: 49.15). When the stimulation was OFF, patients aware of this condition had higher UPDRS motor scores than when they were blinded (mean: 50.7 vs. 47.6). With the stimulation ON, UPDRS motor scores were lower when the patients were aware of the stimulation compared with when they were blinded (mean: 30.6 vs. 34.5). The interaction between these levels was significant (P = 0.049). This variation was important for bradykinesia and was not significant for tremor and rigidity. The authors conclude that the information about the condition of the stimulation enhanced the final clinical effect in opposite directions. The results presented support the role of expectation and placebo effects in STN-DBS in Parkinson's disease patients.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Attente @5 09`
C03	`03`	`X`	`ENG`	`@0 Expectation @5 09`
C03	`03`	`X`	`SPA`	`@0 Expectación @5 09`
C03	`04`	`X`	`FRE`	`@0 Effet placebo @5 10`
C03	`04`	`X`	`ENG`	`@0 Placebo effect @5 10`
C03	`04`	`X`	`SPA`	`@0 Efecto placebo @5 10`
C03	`05`	`X`	`FRE`	`@0 Homme @5 11`
C03	`05`	`X`	`ENG`	`@0 Human @5 11`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 11`
C03	`06`	`X`	`FRE`	`@0 Noyau sousthalamique @5 12`
C03	`06`	`X`	`ENG`	`@0 Subthalamic nucleus @5 12`
C03	`06`	`X`	`SPA`	`@0 Núcleo subtalámico @5 12`
C03	`07`	`X`	`FRE`	`@0 Placebo @5 13`
C03	`07`	`X`	`ENG`	`@0 Placebo @5 13`
C03	`07`	`X`	`SPA`	`@0 Placebo @5 13`
C03	`08`	`X`	`FRE`	`@0 Stimulation cérébrale profonde @4 CD @5 96`
C03	`08`	`X`	`ENG`	`@0 Deep brain stimulation @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso central @5 41`
N21				`@1 338`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0518102 INIST
ET :	Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation
AU :	MERCADO (Rodrigo); CONSTANTOYANNIS (Constantine); MANDAT (Tomasz); KUMAR (Ajit); SCHULZER (Michael); STOESSL (A. Jon); HONEY (Christopher R.)
AF :	Surgical Centre for Movement Disorders, University of British Columbia/British Columbia/Canada (1 aut., 2 aut., 3 aut., 7 aut.); Pacific Parkinson's Disease Research Center, University of British Columbia/British Columbia/Canada (4 aut., 5 aut., 6 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 9; Pp. 1457-1461; Bibl. 32 ref.
LA :	Anglais
EA :	To determine whether the degree to which a patient with Parkinson's disease expects therapeutic benefit from subthalamic nucleus-deep brain stimulation (STN-DBS) influences the magnitude of his or her improved motor response, 10 patients with idiopathic Parkinson's and bilateral STN-DBS were tested after a 12-hour period off medication and stimulation. Four consecutive UPDRS III scores were performed in the following conditions: (a) stimulation OFF, patient aware; (b) stimulation OFF, patient blind; (c) stimulation ON, patient aware; and (d) stimulation ON, patient blind. Statistical significance (P = 0.0001) was observed when comparing main effect ON versus OFF (mean ON: 32.55; mean OFF: 49.15). When the stimulation was OFF, patients aware of this condition had higher UPDRS motor scores than when they were blinded (mean: 50.7 vs. 47.6). With the stimulation ON, UPDRS motor scores were lower when the patients were aware of the stimulation compared with when they were blinded (mean: 30.6 vs. 34.5). The interaction between these levels was significant (P = 0.049). This variation was important for bradykinesia and was not significant for tremor and rigidity. The authors conclude that the information about the condition of the stimulation enhanced the final clinical effect in opposite directions. The results presented support the role of expectation and placebo effects in STN-DBS in Parkinson's disease patients.
CC :	002B17; 002B17G; 002B17F
FD :	Système nerveux pathologie; Parkinson maladie; Attente; Effet placebo; Homme; Noyau sousthalamique; Placebo; Stimulation cérébrale profonde
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux central
ED :	Nervous system diseases; Parkinson disease; Expectation; Placebo effect; Human; Subthalamic nucleus; Placebo; Deep brain stimulation
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Central nervous system
SD :	Sistema nervioso patología; Parkinson enfermedad; Expectación; Efecto placebo; Hombre; Núcleo subtalámico; Placebo
LO :	INIST-20953.354000158780860240
ID :	06-0518102

Links to Exploration step

Pascal:06-0518102

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation</title>
<author><name sortKey="Mercado, Rodrigo" sort="Mercado, Rodrigo" uniqKey="Mercado R" first="Rodrigo" last="Mercado">Rodrigo Mercado</name>
<affiliation><inist:fA14 i1="01"><s1>Surgical Centre for Movement Disorders, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Constantoyannis, Constantine" sort="Constantoyannis, Constantine" uniqKey="Constantoyannis C" first="Constantine" last="Constantoyannis">Constantine Constantoyannis</name>
<affiliation><inist:fA14 i1="01"><s1>Surgical Centre for Movement Disorders, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mandat, Tomasz" sort="Mandat, Tomasz" uniqKey="Mandat T" first="Tomasz" last="Mandat">Tomasz Mandat</name>
<affiliation><inist:fA14 i1="01"><s1>Surgical Centre for Movement Disorders, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kumar, Ajit" sort="Kumar, Ajit" uniqKey="Kumar A" first="Ajit" last="Kumar">Ajit Kumar</name>
<affiliation><inist:fA14 i1="02"><s1>Pacific Parkinson's Disease Research Center, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<affiliation><inist:fA14 i1="02"><s1>Pacific Parkinson's Disease Research Center, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation><inist:fA14 i1="02"><s1>Pacific Parkinson's Disease Research Center, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Honey, Christopher R" sort="Honey, Christopher R" uniqKey="Honey C" first="Christopher R." last="Honey">Christopher R. Honey</name>
<affiliation><inist:fA14 i1="01"><s1>Surgical Centre for Movement Disorders, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0518102</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0518102 INIST</idno>
<idno type="RBID">Pascal:06-0518102</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000801</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation</title>
<author><name sortKey="Mercado, Rodrigo" sort="Mercado, Rodrigo" uniqKey="Mercado R" first="Rodrigo" last="Mercado">Rodrigo Mercado</name>
<affiliation><inist:fA14 i1="01"><s1>Surgical Centre for Movement Disorders, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Constantoyannis, Constantine" sort="Constantoyannis, Constantine" uniqKey="Constantoyannis C" first="Constantine" last="Constantoyannis">Constantine Constantoyannis</name>
<affiliation><inist:fA14 i1="01"><s1>Surgical Centre for Movement Disorders, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mandat, Tomasz" sort="Mandat, Tomasz" uniqKey="Mandat T" first="Tomasz" last="Mandat">Tomasz Mandat</name>
<affiliation><inist:fA14 i1="01"><s1>Surgical Centre for Movement Disorders, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kumar, Ajit" sort="Kumar, Ajit" uniqKey="Kumar A" first="Ajit" last="Kumar">Ajit Kumar</name>
<affiliation><inist:fA14 i1="02"><s1>Pacific Parkinson's Disease Research Center, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<affiliation><inist:fA14 i1="02"><s1>Pacific Parkinson's Disease Research Center, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation><inist:fA14 i1="02"><s1>Pacific Parkinson's Disease Research Center, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Honey, Christopher R" sort="Honey, Christopher R" uniqKey="Honey C" first="Christopher R." last="Honey">Christopher R. Honey</name>
<affiliation><inist:fA14 i1="01"><s1>Surgical Centre for Movement Disorders, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Deep brain stimulation</term>
<term>Expectation</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Placebo</term>
<term>Placebo effect</term>
<term>Subthalamic nucleus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Attente</term>
<term>Effet placebo</term>
<term>Homme</term>
<term>Noyau sousthalamique</term>
<term>Placebo</term>
<term>Stimulation cérébrale profonde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To determine whether the degree to which a patient with Parkinson's disease expects therapeutic benefit from subthalamic nucleus-deep brain stimulation (STN-DBS) influences the magnitude of his or her improved motor response, 10 patients with idiopathic Parkinson's and bilateral STN-DBS were tested after a 12-hour period off medication and stimulation. Four consecutive UPDRS III scores were performed in the following conditions: (a) stimulation OFF, patient aware; (b) stimulation OFF, patient blind; (c) stimulation ON, patient aware; and (d) stimulation ON, patient blind. Statistical significance (P = 0.0001) was observed when comparing main effect ON versus OFF (mean ON: 32.55; mean OFF: 49.15). When the stimulation was OFF, patients aware of this condition had higher UPDRS motor scores than when they were blinded (mean: 50.7 vs. 47.6). With the stimulation ON, UPDRS motor scores were lower when the patients were aware of the stimulation compared with when they were blinded (mean: 30.6 vs. 34.5). The interaction between these levels was significant (P = 0.049). This variation was important for bradykinesia and was not significant for tremor and rigidity. The authors conclude that the information about the condition of the stimulation enhanced the final clinical effect in opposite directions. The results presented support the role of expectation and placebo effects in STN-DBS in Parkinson's disease patients.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MERCADO (Rodrigo)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CONSTANTOYANNIS (Constantine)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MANDAT (Tomasz)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KUMAR (Ajit)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SCHULZER (Michael)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STOESSL (A. Jon)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HONEY (Christopher R.)</s1>
</fA11>
<fA14 i1="01"><s1>Surgical Centre for Movement Disorders, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Pacific Parkinson's Disease Research Center, University of British Columbia</s1>
<s2>British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>1457-1461</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000158780860240</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>32 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0518102</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>To determine whether the degree to which a patient with Parkinson's disease expects therapeutic benefit from subthalamic nucleus-deep brain stimulation (STN-DBS) influences the magnitude of his or her improved motor response, 10 patients with idiopathic Parkinson's and bilateral STN-DBS were tested after a 12-hour period off medication and stimulation. Four consecutive UPDRS III scores were performed in the following conditions: (a) stimulation OFF, patient aware; (b) stimulation OFF, patient blind; (c) stimulation ON, patient aware; and (d) stimulation ON, patient blind. Statistical significance (P = 0.0001) was observed when comparing main effect ON versus OFF (mean ON: 32.55; mean OFF: 49.15). When the stimulation was OFF, patients aware of this condition had higher UPDRS motor scores than when they were blinded (mean: 50.7 vs. 47.6). With the stimulation ON, UPDRS motor scores were lower when the patients were aware of the stimulation compared with when they were blinded (mean: 30.6 vs. 34.5). The interaction between these levels was significant (P = 0.049). This variation was important for bradykinesia and was not significant for tremor and rigidity. The authors conclude that the information about the condition of the stimulation enhanced the final clinical effect in opposite directions. The results presented support the role of expectation and placebo effects in STN-DBS in Parkinson's disease patients.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Attente</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Expectation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Expectación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Effet placebo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Placebo effect</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Efecto placebo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Noyau sousthalamique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Subthalamic nucleus</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Núcleo subtalámico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Placebo</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Placebo</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Placebo</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Stimulation cérébrale profonde</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Deep brain stimulation</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>41</s5>
</fC07>
<fN21><s1>338</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0518102 INIST</NO>
<ET>Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation</ET>
<AU>MERCADO (Rodrigo); CONSTANTOYANNIS (Constantine); MANDAT (Tomasz); KUMAR (Ajit); SCHULZER (Michael); STOESSL (A. Jon); HONEY (Christopher R.)</AU>
<AF>Surgical Centre for Movement Disorders, University of British Columbia/British Columbia/Canada (1 aut., 2 aut., 3 aut., 7 aut.); Pacific Parkinson's Disease Research Center, University of British Columbia/British Columbia/Canada (4 aut., 5 aut., 6 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 9; Pp. 1457-1461; Bibl. 32 ref.</SO>
<LA>Anglais</LA>
<EA>To determine whether the degree to which a patient with Parkinson's disease expects therapeutic benefit from subthalamic nucleus-deep brain stimulation (STN-DBS) influences the magnitude of his or her improved motor response, 10 patients with idiopathic Parkinson's and bilateral STN-DBS were tested after a 12-hour period off medication and stimulation. Four consecutive UPDRS III scores were performed in the following conditions: (a) stimulation OFF, patient aware; (b) stimulation OFF, patient blind; (c) stimulation ON, patient aware; and (d) stimulation ON, patient blind. Statistical significance (P = 0.0001) was observed when comparing main effect ON versus OFF (mean ON: 32.55; mean OFF: 49.15). When the stimulation was OFF, patients aware of this condition had higher UPDRS motor scores than when they were blinded (mean: 50.7 vs. 47.6). With the stimulation ON, UPDRS motor scores were lower when the patients were aware of the stimulation compared with when they were blinded (mean: 30.6 vs. 34.5). The interaction between these levels was significant (P = 0.049). This variation was important for bradykinesia and was not significant for tremor and rigidity. The authors conclude that the information about the condition of the stimulation enhanced the final clinical effect in opposite directions. The results presented support the role of expectation and placebo effects in STN-DBS in Parkinson's disease patients.</EA>
<CC>002B17; 002B17G; 002B17F</CC>
<FD>Système nerveux pathologie; Parkinson maladie; Attente; Effet placebo; Homme; Noyau sousthalamique; Placebo; Stimulation cérébrale profonde</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux central</FG>
<ED>Nervous system diseases; Parkinson disease; Expectation; Placebo effect; Human; Subthalamic nucleus; Placebo; Deep brain stimulation</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Central nervous system</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Expectación; Efecto placebo; Hombre; Núcleo subtalámico; Placebo</SD>
<LO>INIST-20953.354000158780860240</LO>
<ID>06-0518102</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000801 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000801 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0518102
   |texte=   Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation

Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri